Earnings
Candel Targets Mid-2027 Prostate-Cancer Application With Assay Work Still Shaping Its Timing
The cancer-treatment developer expects its $203.1 million cash balance to support operations into the second quarter of 2028.
Candel Therapeutics (CADL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The cancer-treatment developer expects its $203.1 million cash balance to support operations into the second quarter of 2028.
SEC Filings
Jefferies will earn a 3% sales commission, while Candel controls when to request sales and the minimum prices.